Insider Trading Alert - MJN, SNX, N, ITRI And ILMN Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Friday, Nov. 1, 2013, 100 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $2,920.00 to $142,506,400.00.

Highlighted Stocks Traded by Insiders:

Mead Johnson Nutrition Company (MJN) - FREE Research Report

Singer Robert S who is Director at Mead Johnson Nutrition Company bought 500 shares at $82.46 on Nov. 1, 2013. Following this transaction, the Director owned 20,532 shares meaning that the stake was reduced by 2.5% with the 500 share transaction.

The shares most recently traded at $81.75, down $0.71, or 0.87% since the insider transaction. Historical insider transactions for Mead Johnson Nutrition Company go as follows:

  • 4-Week # shares sold: 10,000
  • 12-Week # shares bought: 10,000
  • 12-Week # shares sold: 30,525
  • 24-Week # shares bought: 10,000
  • 24-Week # shares sold: 50,525

The average volume for Mead Johnson Nutrition Company has been 1.5 million shares per day over the past 30 days. Mead Johnson Nutrition Company has a market cap of $16.5 billion and is part of the consumer goods sector and food & beverage industry. Shares are up 24.37% year to date as of the close of trading on Friday.

Mead Johnson Nutrition Company manufactures, distributes, and sells infant formulas, children's nutrition, and other nutritional products. The stock currently has a dividend yield of 1.67%. The company has a P/E ratio of 26.3. Currently there are 4 analysts that rate Mead Johnson Nutrition Company a buy, no analysts rate it a sell, and 8 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MJN - FREE

TheStreet Quant Ratings rates Mead Johnson Nutrition Company as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, growth in earnings per share, expanding profit margins, good cash flow from operations and solid stock price performance. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value. Get the full Mead Johnson Nutrition Company Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Synnex Corporation (SNX) - FREE Research Report

Miau Matthew who is Director at Synnex Corporation sold 40,000 shares at $61.51 on Nov. 1, 2013. Following this transaction, the Director owned 5.6 million shares meaning that the stake was reduced by 0.72% with the 40,000 share transaction.

The shares most recently traded at $61.16, down $0.35, or 0.58% since the insider transaction. Historical insider transactions for Synnex Corporation go as follows:

  • 4-Week # shares sold: 226,266
  • 12-Week # shares sold: 367,939
  • 24-Week # shares sold: 367,939

The average volume for Synnex Corporation has been 198,100 shares per day over the past 30 days. Synnex Corporation has a market cap of $2.3 billion and is part of the services sector and diversified services industry. Shares are up 78.3% year to date as of the close of trading on Friday.

SYNNEX Corporation provides distribution and business process outsourcing (BPO) services to resellers, retailers, and original equipment manufacturers (OEMs) primarily in North America. The company operates in two segments, Distribution Services and Global Business Services (GBS). The company has a P/E ratio of 19.6. Currently there are 3 analysts that rate Synnex Corporation a buy, 1 analyst rates it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SNX - FREE

TheStreet Quant Ratings rates Synnex Corporation as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, solid stock price performance and increase in net income. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Synnex Corporation Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

NetSuite (N) - FREE Research Report

Farrington Deborah A who is Director at NetSuite sold 29,094 shares at $101.02 on Nov. 1, 2013. Following this transaction, the Director owned 0 shares meaning that the stake was reduced by 100% with the 29,094 share transaction.

The shares most recently traded at $99.08, down $1.94, or 1.95% since the insider transaction. Historical insider transactions for NetSuite go as follows:

  • 4-Week # shares sold: 20,000
  • 12-Week # shares sold: 76,377
  • 24-Week # shares sold: 106,223

The average volume for NetSuite has been 343,200 shares per day over the past 30 days. NetSuite has a market cap of $7.5 billion and is part of the technology sector and computer software & services industry. Shares are up 49.9% year to date as of the close of trading on Friday.

NetSuite Inc. provides cloud-based financials/enterprise resource planning (ERP) software suites in the United States and internationally. Currently there are 6 analysts that rate NetSuite a buy, no analysts rate it a sell, and 8 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on N - FREE

TheStreet Quant Ratings rates NetSuite as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and weak operating cash flow. Get the full NetSuite Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Itron (ITRI) - FREE Research Report

Glanville Thomas S who is Director at Itron sold 603 shares at $42.10 on Nov. 1, 2013. Following this transaction, the Director owned 22,803 shares meaning that the stake was reduced by 2.58% with the 603 share transaction.

The shares most recently traded at $42.58, up $0.48, or 1.13% since the insider transaction.

The average volume for Itron has been 319,300 shares per day over the past 30 days. Shares are down 4.22% year to date as of the close of trading on Friday.

Itron, Inc. provides metering solutions, meter data management software, and knowledge application solutions to electric, natural gas, and water utilities worldwide. The company has a P/E ratio of 72.3. Currently there are 5 analysts that rate Itron a buy, 1 analyst rates it a sell, and 7 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ITRI - FREE

TheStreet Quant Ratings rates Itron as a hold. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and poor profit margins. Get the full Itron Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Illumina (ILMN) - FREE Research Report

Walt David R who is Director at Illumina sold 5,000 shares at $93.02 on Nov. 1, 2013. Following this transaction, the Director owned 911,488 shares meaning that the stake was reduced by 0.55% with the 5,000 share transaction.

The shares most recently traded at $95.65, up $2.63, or 2.74% since the insider transaction. Historical insider transactions for Illumina go as follows:

  • 4-Week # shares sold: 5,000
  • 12-Week # shares sold: 26,627
  • 24-Week # shares sold: 58,096

The average volume for Illumina has been 989,600 shares per day over the past 30 days. Illumina has a market cap of $11.7 billion and is part of the health care sector and drugs industry. Shares are up 68.21% year to date as of the close of trading on Friday.

Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for the analysis of genetic variation and biological function in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa. The company has a P/E ratio of 70.8. Currently there are 9 analysts that rate Illumina a buy, no analysts rate it a sell, and 9 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ILMN - FREE

TheStreet Quant Ratings rates Illumina as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, good cash flow from operations, increase in net income, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Illumina Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Data for this article provided by Zacks Investment Research

null

More from Markets

U.S. Crude Oil Hits Fresh 3-Year Highs as Gasoline Heads to $3 a Gallon

U.S. Crude Oil Hits Fresh 3-Year Highs as Gasoline Heads to $3 a Gallon

Stocks Waver Amid Progress on U.S.-China Trade; Dow Slips

Stocks Waver Amid Progress on U.S.-China Trade; Dow Slips

Jim Cramer: Schlumberger Predicted the Rise in Oil Prices

Jim Cramer: Schlumberger Predicted the Rise in Oil Prices

Jim Cramer on Zillow's New Business: Buying and Selling Homes

Jim Cramer on Zillow's New Business: Buying and Selling Homes

Jim Cramer on the Markets: It's Natural to Have Some Profit Taking

Jim Cramer on the Markets: It's Natural to Have Some Profit Taking